Epcoritamab obtains accelerated approval for relapsed/refractory DLBCL
Last Updated: Monday, September 25, 2023
Based on data from the phase 1/2 EPCORE NHL-1 trial, T-cell–engaging bispecific antibody epcoritamab-bysp received accelerated FDA approval for the treatment of adult patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma (HGBL), following 2 or more lines of systemic therapies.
Advertisement
News & Literature Highlights
